Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

84.42USD
4:01pm EDT
Change (% chg)

$0.06 (+0.07%)
Prev Close
$84.36
Open
$84.14
Day's High
$85.05
Day's Low
$84.07
Volume
768,980
Avg. Vol
1,410,096
52-wk High
$86.13
52-wk Low
$64.25

Latest Key Developments (Source: Significant Developments)

Boehringer Ingelheim says jardiance becomes first type 2 diabetes medicine in EU to include cardiovascular death reduction data in label
Thursday, 26 Jan 2017 08:16am EST 

Eli Lilly And Co : Boehringer ingelheim- jardiance (empagliflozin) becomes first type 2 diabetes medicine in eu to include cardiovascular death reduction data in label .Boehringer ingelheim- approved product information now includes data on reduction of risk of cv death in patients with t2d, established cv disease.  Full Article

Inovalon announces agreement with Boehringer Ingelheim to support outcome-based contracting
Monday, 23 Jan 2017 07:55am EST 

Inovalon Holdings Inc : Inovalon announces agreement with Boehringer Ingelheim to support outcome-based contracting .Inovalon Holdings Inc - has entered into an agreement with Boehringer Ingelheim Pharmaceuticals Inc.  Full Article

Colucid Pharmaceuticals says termination fee of $34 mln to be payable to Eli Lilly upon termination
Wednesday, 18 Jan 2017 08:38am EST 

Colucid Pharmaceuticals Inc :Colucid Pharmaceuticals - upon termination of deal under specified circumstances, co will be required to pay Eli Lilly termination fee of $34 million.  Full Article

Lilly and CoLucid Pharmaceuticals announce agreement for Lilly to acquire CoLucid
Wednesday, 18 Jan 2017 06:45am EST 

CoLucid Pharmaceuticals Inc : Lilly and CoLucid Pharmaceuticals announce agreement for Lilly to acquire CoLucid . CoLucid Pharmaceuticals Inc says deal for $46.50 per share . CoLucid Pharmaceuticals Inc says deal for $960 million . CoLucid Pharmaceuticals Inc says Lilly is expecting to recognize a financial charge of approximately $850 million (no tax benefit), or approximately $0.80 per share from deal . Deal is an all-cash transaction . Lilly's reported earnings per share guidance in 2017 is expected to be reduced by amount of charge . Says data read-out for second phase 3 trial, Spartan, is expected in second half of 2017 . There will be no change to Lilly's non-GAAP earnings per share guidance as a result of this transaction .Says if Spartan phase 3 trial is positive, submission of Lasmiditan for U.S. Regulatory approval could occur in 2018.  Full Article

U.S. FDA extends review period for Baricitinib, an investigational rheumatoid arthritis treatment
Friday, 13 Jan 2017 04:51pm EST 

Incyte Corp : U.S. FDA extends review period for baricitinib, an investigational rheumatoid arthritis treatment . Incyte Corp says delay does not affect Lilly's previously-issued financial guidance for 2017 . Incyte - FDA extended action date to allow time to review additional data analyses recently submitted by Lilly in response to FDA's information requests .Incyte- Submission of additional information was determined by FDA to constitute major amendment to NDA, resulting in extension of PDUFA date by 3 months.  Full Article

U.S. appeals court rejects Teva appeal in Lilly patent case over Alimta
Thursday, 12 Jan 2017 10:16am EST 

U.S. Appeals Court rules for Eli Lilly and against Teva Pharmaceutical in Alimta patent case -- court ruling : U.S. Court of appeals for the federal circuit upholds lower court finding that teva was liable for inducing infringement by doctors Further company coverage: [LLY.N].  Full Article

Eli Lilly provides 2017 financial forecast and 2016 update
Thursday, 15 Dec 2016 06:25am EST 

Eli Lilly And Co : Lilly provides 2017 financial guidance and 2016 update, reaffirms financial expectations through the remainder of the decade . Sees FY 2016 earnings per share $2.57 to $2.67 . Sees FY 2017 revenue $21.8 billion to $22.3 billion . Reaffirms FY 2016 non-GAAP earnings per share view $3.50 to $3.60 . Sees FY 2016 revenue $20.8 billion to $21.2 billion . Reaffirms FY 2017 non-GAAP earnings per share view $4.05 to $4.15 including items . Reaffirms FY 2017 earnings per share view $3.51 to $3.61 including items . FY 2016 earnings per share view $3.52, revenue view $20.99 billion -- Thomson Reuters I/B/E/S . Confirmed potential to launch 20 new products in 10 years from 2014 through 2023 . Eli Lilly and Co says capital expenditures are still expected to be approximately $1.0 billion for 2016 . Sees 2017 capital expenditures approx. $1.2 billion . Eli Lilly and Co - Reaffirmed its commitment to achieve an opex-to-revenue ratio of 50 percent or less in 2018 . FY 2017 earnings per share view $3.97, revenue view $21.67 billion -- Thomson Reuters I/B/E/S .Eli Lilly and Co - Research and development expenses are expected to be in range of $4.9 billion to $5.1 billion in 2017.  Full Article

Eli lilly says Solanezumab did not meet primary endpoint in expedition3 clinical trial
Thursday, 8 Dec 2016 09:15pm EST 

Eli Lilly And Co : Will not pursue regulatory submissions for Solanezumab for treatment of mild dementia due to AD . Solanezumab did not meet primary endpoint in expedition3 clinical trial .Lilly announces detailed results of solanezumab phase 3 expedition3 study at the clinical trials on alzheimer's disease (CTAD) 2016 meeting.  Full Article

FDA approves jardiance to reduce cardiovascular death in adults with Type 2 diabetes
Friday, 2 Dec 2016 01:08pm EST 

U.S. FDA : FDA approves jardiance to reduce cardiovascular death in adults with type 2 diabetes .U.S. FDA - approves Boehringer Ingelheim Pharma's jardiance to reduce cardiovascular death in adults with Type 2 diabetes.  Full Article

Athenex and Lilly enter clinical collaboration agreement
Friday, 18 Nov 2016 08:00am EST 

Athenex Inc : Athenex will be sponsor of clinical trial and Lilly will supply Cyramza . Athenex inc - patient enrollment, currently expected to start in 2017, is planned at sites in U.S. And asia . Athenex Inc - new Phase1b study to evaluate combination of Oraxol and Cyramza in patients with advanced gastric cancer .Press release - Athenex and Lilly enter clinical collaboration agreement.  Full Article

More From Around the Web

BRIEF-Eli Lilly and Co says CEO John Lechleiter's 2016 total compensation was $18.4 mln

* CEO John C. Lechleiter's 2016 total compensation was $18.4 million versus $16.6 million in 2015